$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
奥拉帕尼治疗HER2转移性乳腺癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗HER2阴性乳腺癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼+PD-L1抗体在转移性去势抵抗性前列腺癌中的活性
2025-10-19 11:44:20
Check Details
奥拉帕尼+PD-L1抗体或西地尼布+PD-L1抗体治疗女性癌症的安全性和临床活性:I期研究
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA突变的HER2转移性乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼的真实世界应用和结果
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗HER-2阴性的转移性乳腺癌的疗效
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA突变的HER2阴性转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA突变转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗癌症的有效性和安全性:随机对照试验的meta分析
2025-10-19 11:44:20
Check Details
舒尼替尼治疗移性乳腺癌患者
2025-10-19 11:44:20
Check Details
1
2
...
1646
1647
1648
1649
1650
1651
1652
...
4154
4155
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sotorasib (Lumakras®): The First KRAS Inhibitor Revolutionizing Non-Small Cell Lung Cancer Treatment
2
LONSURF® (Trifluridine/Tipiracil): Unveiling the Global R&D and Supply Chain Behind the Oral Chemotherapy
3
FDA Approves Lilly's Inluriyo (Imlunestrant) for ESR1-Mutant Advanced Breast Cancer
4
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
5
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
6
Adagrasib Medication Management Guide for Special Populations
7
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
8
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
9
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
10
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
11
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
12
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer